Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Mantle-Cell 1Lymphoma 1Leukemia, Myeloid, Acute 1Diffuse Intrinsic Pontine Glioma 1Cut-Off Value 1Carcinosarcoma 1Carcinoma, Endometrioid 1

Interventions

Rituximab 27acalabrutinib 15ibrutinib 13Cyclophosphamide 12Lenalidomide 10CT-P10 10zanubrutinib 9venetoclax 9Magnetic Resonance Spectroscopy 8obinutuzumab 7Specimen Handling 7Cytarabine 7Bendamustine Hydrochloride 7pirtobrutinib 6fludarabine 6Biopsy 6glofitamab 5fludarabine phosphate 5Peripheral Blood Stem Cell Transplantation 5Cyclosporine 5brexucabtagene autoleucel 4Whole-Body Irradiation 4Mycophenolic Acid 4Vincristine 3Stem Cell Transplantation 3Sirolimus 3Methotrexate 3Etoposide 3Doxorubicin 3Cyclosporins 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Mantle-Cell × Fluid Therapy × 90 days × Clear all
NCT03267433 2026-05-05

Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

Eastern Cooperative Oncology Group

Phase 3 Active not recruiting
689 enrolled
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡